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Abstract 
Purpose: Our study determined the prevalence of polypharmacy and drug-drug interactions 
(DDIs) in older and younger prisoners, and compared if age group is associated with risks of 
polypharmacy and DDIs.  
Methods: For 380 prisoners from Switzerland (190 were 49 years and younger; 190 were 50 
years and older), data concerning their medication use were gathered. MediQ identified if 
interactions of two or more substances could lead to potentially adverse DDI. Data were 
analysed using descriptive statistics and generalized liner mixed models. 
Results: On average, older prisoners took 3.8 medications, while younger prisoners took 2.1 
medications. Number of medications taken on one reference day was higher by a factor of 2.4 
for older prisoners when compared to younger prisoners (p = .002). The odds of 
polypharmacy was significantly higher for older than for younger prisoners (≥5 medications: 
Odds ratio = 5.52, p = .035). Age group analysis indicated that for potentially adverse DDI 
there was no significant difference (Odds ratio = 0.94; p = 0.879). However, when controlling 
for the number of medication, the risk of adverse DDI was higher in younger than older 
prisoners, but the result was not significant. 
Originality/Value: Older prisoners are at a higher risk of polypharmacy but their risk for 
potentially adverse DDI is not significantly different from that of younger prisoners. Special 
clinical attention must be given to older prisoners who are at risk for polypharmacy. Careful 
medication management is also important for younger prisoners who are at risk of very 
complex drug therapies. 
Key words: polypharmacy, polymedication, drug-drug interactions, prison, older prisoners 
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Introduction 
Polypharmacy or polymedication literally means the use of more than one drug at any 
time. In the literature, it frequently denotes the concurrent use of five or more drugs 
(Jokanovic et al., 2015; Masnoon et al., 2017; Mosshammer et al., 2016; WHO 2018). 
Polypharmacy is sometimes also negatively connoted as the inappropriate use of multiple 
medications or as the use of medications that are not clinically indicated (Fulton and Allen 
2005; Jokanovic et al., 2015). To date, there is neither an agreed-upon definition of 
polypharmacy nor a cut-off point regarding the number of medications involved (Masnoon et 
al., 2017). However, it is accepted that there are certain risks associated with polypharmacy. 
For instance, polypharmacy increases the risk for adverse drug reactions and decreases drug 
compliance (Hajjar et al., 2007; Shah and Hajjar 2012). In the elderly population, it is 
associated with inappropriate prescribing, functional decline, and an increased risk for 
geriatric syndromes (Hajjar et al., 2007; Maher et al., 2014; Shah and Hajjar 2012). 
Polypharmacy also increases the risk of drug-drug interactions (DDIs) (Hajjar et al., 2007; 
Maher et al., 2014). A DDI is a situation in which one drug modifies the effect of another 
when both are taken together (Marengoni and Onder 2015) and adverse DDI can increase 
toxicity or reduce effectiveness of the substances (Preston 2016). A potentially adverse DDI is 
one that can be predicted from the known pharmacological properties of the substances 
involved. The clinical outcome of each DDI depends on individual risk factors such as age, 
genetic disposition, current conditions, and treatment factors like dosage or duration of the 
therapy. Thus, only a small number of potentially adverse DDIs lead to clinically significant 
adverse drug reactions (Horn and Hansten 2011; Seymour and Routledge 1998). That is, not 
all potentially adverse DDIs are harmful. Moreover, the administration of drugs known to 
interact adversely is sometimes necessary and is an advisable practice under strict monitoring 
and when appropriate precautions are taken (Preston 2016). To decide whether a potentially 
adverse DDI is of clinical significance, it is necessary to examine each case individually, 
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considering additional factors like medical history, patient age, or current biomarkers (e.g. 
laboratory values or electrocardiogram recordings) (Preston 2016; van Roon et al., 2005).  
DDIs are an important issue when caring for older and frail patients because of their 
greater disease burden and consequently disproportionate use of medications (Prince et al., 
2015). Older patients’ greater intake of medications is a concern in light of physiological 
changes such as decreased renal and liver functions, which at the same time increases the risk 
for adverse drug reactions (Ballentine 2008; Fulton and Allen 2005). It is estimated that DDIs 
are responsible for 4.8% of all hospital emergency department visits (Becker et al., 2007), and 
that appropriate prescribing has the potential to consequently reduce emergency department 
visits, hospital visits, and mortality (Gillespie et al., 2009; Spinewine et al., 2007).  
Compared to older adults in the community, the prevalence of (multi-)morbidity is 
even higher among older prisoners (Binswanger et al., 2009; Fazel et al., 2001). Studies report 
that older prisoners live with more illness than younger ones (Fazel et al., 2001; Fazel and 
Baillargeon 2011; Wangmo et al., 2015; Watson 2016). Prisoners are often defined as “old” 
from 50 years of age due to accelerated aging (Loeb and AbuDagga 2006; Loeb et al., 2008). 
Today, older prisoners, aged 50 and more, are still a minority in the Swiss prison population 
(Moschetti et al., 2015) as well as prison population in other countries. However, they form 
one of the fastest growing prison sub-groups (Human Rights Watch 2012). The illness 
epidemiology of older prisoners coupled with their rising number hold increasing public 
health importance (Fazel and Baillargeon 2011), nationally and internationally. 
There are numerous studies investigating polypharmacy among older people in general  
(Fulton and Allen 2005; Jokanovic et al., 2015; Maher et al., 2014; Shah and Hajjar 2012), 
studies examining the health of prisoners (Binswanger et al., 2009; Pfortmueller et al., 2013), 
and of older prisoners in particular (Fazel et al., 2004; Loeb and AbuDagga 2006; Loeb et al., 
2008; Wangmo et al., 2015). Only a few studies have explored the drug prescribing practices 
for prisoners of all ages (Elger et al., 2002; Elger et al., 2004; Griffiths et al., 2012) and very 
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few have specifically examined the medication use among older prisoners (Fazel et al., 2004; 
Williams et al., 2010).  
To our knowledge, polypharmacy and DDIs among prisoners have hardly been studied 
and neither has any study compared whether age group is associated with polypharmacy and 
drug interactions among this population. Therefore, the present study aims to fill this research 
gap by addressing four questions: (a) What are the prevalence of polypharmacy and DDIs 
among older and younger prisoners in Switzerland? (b) Are there age group difference in the 
prevalence of polypharmacy and DDIs? (c) Which medications (active pharmaceutical 
ingredients) are primarily involved in potentially adverse DDIs? (d) What is the prevalence of 
actual clinically significant adverse drug reactions among older and younger prisoners? This 
study provides epidemiological data to improve medication safety and consequently, the 
quality of medical care provided to older and younger prisoners in Switzerland and 
comparable countries.  
Methods 
Sample and data collection 
This study is part of a larger project entitled “Agequake in Prisons”. The aim of the 
project was to understand the overall health and healthcare circumstances of aging prisoners 
in Switzerland. It considers not only prisoners’ medication use, but also a multitude of other 
health related factors such as disease burden and healthcare utilization (Wangmo et al., 2015; 
Wangmo et al., 2016). Fifteen prisons with a capacity of 2,198 places (76.4%) out of a total of 
26 prisons fulfilling the study’s inclusion criteria (long-term imprisonments, >20 places, 
housing prisoners aged ≥50, from German and French speaking cantons of Switzerland) 
agreed to participate in the study (see (Wangmo et al., 2015) for in-depth information). Eleven 
prisons declined participation due to lack of time and other resources. Ethics committees of all 
involved cantons approved the study.  
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Medical records of all prisoners, aged 50 and older, were collected from the 
participating prisons except for one, for which half of the sample of older prisoners’ data were 
collected. From each prison, the same number of medical records belonging to younger 
prisoners (<50 years) was randomly collected to have a basis for comparisons between 
younger and older prisoners (see (Wangmo et al., 2015) for more information). Two research 
assistants visited the prisons between November 2011 and April 2014 and gathered data from 
the medical records. Concerning medication use, they extracted information on the medication 
names, type of prescription, start and stop of prescription, and status of medication at the day 
of data recording, e.g. active or not active. Medication names were entered along with their 
corresponding Anatomical Therapeutic Chemical Classification System (ATC) codes 
(www.whocc.no/atc_ddd_index/). The data entered were checked by independent assistants 
for consistency. 
Twenty six medical records of female prisoners from two prisons were excluded 
because they cannot be treated with male prisoners as a homogenous group (Watson 2016) 
and their number was too small to carry out representative separate analyses. These two 
prisons are the only ones that incarcerate female prisoners with long-term sentences (please 
refer to Handtke and colleagues (2015) for information). Therefore, in this study, data of 380 
male prisoners from 13 prisons were used and analysed. 
Operationalisation of variables 
Polypharmacy was measured by the number of medications taken by the individual 
prisoner on one single reference day (i.e. seven days before data assessment). It was defined 
as the concurrent use of two (polypharmacy in the ‘literal’ sense) or five (polypharmacy as 
often defined in the literature) or more medications.  
Medications were drugs approved by the Swiss Agency for Therapeutic Products. 
Medications contain one or more active pharmaceutical ingredient(s). If a prisoner had the 
same prescription twice on the reference day, although in different “strength” (e.g. Olfen-
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100® and Olfen-50®), those were counted as one medication (e.g. Olfen-150). A number of 
topical preparations like ointments that have no systemic effect and thus, not known to induce 
interactions were counted in the number of medications (polypharmacy) but excluded from 
the DDI analyses. For practical reasons, all vitamins and minerals sometimes containing a 
multitude of different active pharmaceutical ingredients were also excluded from the DDI 
analysis (but included in the medication count).  
In this paper, the term potentially adverse DDI is used to refer to a possibly harmful 
adverse interaction of pairs of two active pharmaceutical ingredients, as identified by the 
clinical decision support software MediQ (https://www.mediq.ch) with moderate (level 3) or 
severe risk (level 4). If that interaction is, according to the estimation of two experienced 
clinical pharmacists (ML and RH), likely to cause clinically relevant adverse drug reactions, 
we refer to it as “A” - clinically relevant DDI. Here, we distinguish further between clinically 
relevant DDIs that are “A1” - caused by a presumed prescription error or “A2” - state of the 
art for the specific patient since there is no better solution available. In contrast, if that level 3 
or 4 interaction is, according to the expertise of the pharmacists, not of clinical relevance for 
the patient, we refer it as “B” - DDI not of clinical relevance. Here, we differentiate between 
state of the art prescriptions (“B1”) and clinically not relevant combinations, nevertheless 
likely to be unintended and the result of inattentiveness (“B2” - harmless prescription error 
probably without clinical relevance). If a drug combination requires constant monitoring of 
the patient, but relevant information is lacking in the available data from the prisoner’s file, 
we refer to “C”- monitoring needed but information lacking. 
Data management 
Our study is based on medications that were administered to and taken by the prisoner 
on the reference day, including firm prescriptions, vaccinations, and medications handed out 
to the patient upon request. Excluded from all analyses were provisional prescriptions (i.e. pro 
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re nata medications) if it was not known whether those were administered on the reference 
day, and medications for which the type of prescription (firm or pro re nata) was not clear. 
Ideally, the medical records contained information on the medication names, type of 
prescription, start and stop of each prescription, and status of medication on the day of data 
recording1. However, if the start date was not available, the medication was dropped from the 
analysis. When the start date was available but the stop date was not available, and the 
medication was recorded as status “active”, stop date was considered equal to date of data 
recording. If the status was “unknown”, the stop date was considered equal to start date and 
the medication as taken on this one day. If the start date was available but the stop date was 
not, and the medication was recorded as status “not active”, “taken once” or “regularly” the 
day of data recording in the prison, the stop date was considered equal to the start date and the 
medication as taken on this day. 
Data analyses 
After data cleaning, all medications that were identified as active on the reference day 
were imported to MediQ software using a self-developed script/code file written in R (version 
3.2.3) that extracted information about all pairwise drug-drug (active ingredients) interactions. 
MediQ was selected because it allows a comparison of an unlimited number of medications 
simultaneously. MediQ compares two active pharmaceutical ingredients (instead of drugs or 
drug-classes) at a time and its algorithms are primarily based on information related to the 
substances. Furthermore, important aspects like dosage or route of administration are 
provided as free text information for each interaction identified by the algorithms. MediQ 
differentiates between four interaction levels: highly relevant interaction, often contra-
indicated (level 4, red); potentially clinical relevant interaction, monitoring warranted (level 3, 
orange); low interaction potential, only relevant in especially vulnerable cases (level 2, 
                                                            
1 In one prison (XIII), type of prescription and stop date was available from the medical records only for very few medications. Not to lose an 
important amount of information, we added a presumed type of prescription and stop dates based on general prescription advices for certain 
drug classes (e.g. antidepressants). 
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yellow); and no indication for an interaction (level 1, grey) (cf. www.mediq.ch). We focused 
on level 4 and 3 interactions in our DDI analysis, leaving out the minor ones, as it has been 
shown that risk ratings with more than three levels can be confusing and the restriction of 
analysis to severe and moderate DDIs is associated with a rise in sensitivity and positive 
predictive power (Vonbach et al., 2008). 
Consequently, two pharmacists individually examined all combinations of active 
pharmaceutical ingredients identified as potentially harmful adverse interactions (levels 3 and 
4) and classified the interactions according to their actual clinical relevance into the categories 
explained above. A final classification of each individual drug combination for a patient was 
decided upon mutual agreement between the pharmacists and one of the first authors (BA).  
We analysed the data using descriptive statistics and generalized liner mixed models 
(GLMM) (Agresti 2003) to examine if there was a difference between older and younger 
prisoners experiencing polypharmacy and potentially adverse DDI, with age group as fixed 
effect and prison as random intercept. The outcome of the first model (number of 
medications) indicated whether there was a difference between younger and older prisoners in 
the number of medications taken. In all remaining models, outcomes were dichotomous 
assessing whether polypharmacy or potentially adverse DDI according to the respective 
definition differed by age group. Data analysis was carried out using IBM SPSS Statistics 22. 
Results 
The final dataset comprised 190 younger (20 - 49 years) and 190 older (50 - 75 years) 
male prisoners with mean ages of 34.3 (SD 7.4) and 58.8 (SD 5.8) years, respectively. Mean 
time served in prison at day of data recording was 2.5 (SD 2.5) years for younger and 5.2 (SD 
6.3) years for older prisoners.  
Polypharmacy among younger and older male prisoners 
Younger male prisoners (n=190) took a total of 156 medications on one reference day, 
comprising firm prescriptions, vaccinations, and other medications handed out to them. A 
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majority (60%) of them took no medications on the reference day, while 20.5% took one, 
10% two, and 9.5% three or more medications (Table 1). Concerned by polypharmacy (≥2 
medications) were roughly one in five younger prisoners (19.5%), while only 3.2% had 
polypharmacy of five or more medications. 
Older prisoners (n=190) took a total of 409 medications on one reference day. In the 
older age group, 43.2% had taken no medication on the reference day, 16.3% have taken one, 
12.1% two, and 28.4% three or more medications (Table 1). Polypharmacy (≥2 medications) 
was observed in 40.5% of older prisoners, while 14.7% were taking five or more medications.  
Table 2 presents findings from the GLMM. The number of medications taken on one 
reference day was higher by a factor of 2.4 for older prisoners when compared to younger 
prisoners (Risk ratio = 2.36; p = .002). Similarly, the odds for polypharmacy was significantly 
higher for older than for younger prisoners (≥2 medications on reference day: Odds ratio = 
3.01, p = .002; ≥5 medications on reference day: Odds ratio = 5.52, p = .035). 
Potentially adverse DDIs among younger and older male prisoners 
Among younger prisoners, a total of 251 combinations of active pharmaceutical 
ingredients2 were tested for interactions using MediQ software. As shown in Table 3, only 25 
combinations (10.0%) had a moderate potential (level 3, orange), and there was no indication 
of a severe (level 4, red) risk for adverse DDI. This means that among all younger prisoners 
with at least two medications on the reference day (n=37), 14 individuals (37.8%) were 
affected by at least one potentially adverse drug-drug combination level 3, moderate alert.  
Among older prisoners, a total of 1,383 combinations of active pharmaceutical 
ingredients were tested for interactions of which only 70 combinations (5.1%) had a moderate 
interaction (level 3, orange), and one combination (0.1%) presented a severe (level 4, red) risk 
for potentially adverse DDI. Looking at all older prisoners with at least two medications on 
                                                            
2The number of combinations of active pharmaceutical ingredients differs from the number of drug combinations as some drugs contain 
multiple active pharmaceutical ingredients. Thus, in some cases (n=10) level 1 interactions (i.e. “no potential for interaction”) are produced 
in individuals with one medication, only.   
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the reference day (n=77), 28 (36.4%) were concerned by at least one potentially adverse drug-
drug combination (level 3 moderate). One prisoner (1.3%) had a level 4 alert. 
Age group analysis (see Table 2) for potentially adverse DDIs indicated that there was 
no age group difference between older and younger prisoners (Odds ratio = 0.94; p = 0.879). 
However, when we adjusted the model for number of medications taken in light of the fact 
that older prisoners took more medications than younger prisoners, the results slightly 
changed (Odds ratio = 0.34; p=0.07, i.e. older prisoners at lower risk than younger prisoners).  
Medication combinations causing potentially adverse DDIs 
In total, 95 combinations for 42 individuals depicted potentially adverse DDIs of 
moderate risk (level 3, orange). One combination in an older individual, led to a high risk alert 
(level 4, red). However, the pharmacists deemed this latter combination as not clinically 
relevant after detailed analysis. Thus, this combination was neglected for the following 
analyses. Table 4 provides a list of all active pharmaceutical ingredients and the 
corresponding medications that resulted in potentially adverse DDIs as well as the risk ratios 
(RR). The RR is the number of individuals concerned by potentially adverse DDI caused by a 
certain active pharmaceutical ingredient in relation to the total number of individuals with this 
prescription. Pharmaceutical ingredient with the highest RR for potentially adverse DDIs was 
escitalopram (which interacted with tizanidine, omeprazole, topiramate, and quetiapine). 
In younger prisoners, the substance resulting most often in potentially adverse DDIs is 
methadone (interacting with diazepame, zolpidem, tizanidin, quetiapine, lorazepame, 
zuclopenthixole, propranolol or midazolame), while in older prisoners, the substance in 
adverse DDIs is ASS (interacting with ibuprofen, diclofenac, clopidogrel, budesonide, 
naproxene, phenprocoumon or heparine).  
Clinically relevant adverse drug reactions  
In younger prisoners, according to the evaluation of our two clinical pharmacists, of 
the 25 drug combinations which were identified as potentially adverse DDIs (level 3, orange 
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alert), eight combinations (32.0%) were classified as clinically relevant “A” (Table 5, second 
column; also see Table 3). Additionally, one combination (4.0%) was classified by the 
pharmacists as clinically not relevant “B” for the individual patient, while they found that the 
prescription of another 16 drug-drug combinations (64.0%) would require monitoring of the 
patient “C” but information about such practice was not available from the medical records, 
which made a final judgement of the individual cases impossible. 
In older prisoners, the pharmacists classified 11 combinations (15.7%) out of a total of 
70 potentially adverse DDIs as clinically relevant “A” (Table 5, third column). A total of 20 
combinations (28.6%) were classified as clinically irrelevant “B” in the individual patient, 
while the prescription of another 39 drug-drug combinations (55.7%) would require 
monitoring “C” but information about such practice was not available. Similar analyses were 
carried out using individuals as the basis instead of drug combinations (refer to Table 5).  
Discussion 
Polypharmacy and DDIs are serious medical concerns and studies evaluating them in 
the prison context are lacking. To our knowledge, this study is one of the very few to examine 
polypharmacy among prisoners and the first to explore potentially adverse DDIs among older 
and younger prisoners. Our results hence provide valuable and much needed data to 
understand medication prescription practices in prisons. It adds new information to the body 
of knowledge available on health and healthcare of older prisoners in Switzerland in particular 
and prisoners in general (Moschetti et al., 2015; Wangmo et al., 2015; Wangmo et al., 2016; 
Williams et al., 2010).  
With regard to the research questions posed in this study, first, we find that one in two 
prisoners were administered at least one medication on the reference day. Among individuals 
who were administered at least one medication, the mean number of medications older 
prisoners took was 3.8 and younger prisoners, 2.1 medications. It is difficult to compare our 
results with studies carried out in the general population not only because of their inherent 
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differences but also because general population studies often present information on three 
time points, that is, before, during, and after hospitalization (Bucsa et al., 2013; Johnell and 
Klarin 2007; Vonbach et al., 2008). If we assume that our data represents before 
hospitalization information and disregard situational differences, then our findings could be 
deemed comparable. For instance, Bucşa and colleagues (2013) found a mean of four drugs 
taken at the same time by older patients before hospital admission, and Vonbach and 
colleagues (2008) also noted four drugs before hospitalization.  
Nearly one in three prisoners in our sample was characterised as having polypharmacy 
defined as the use of two or more medications on a reference day. This proportion reduced to 
approximately one in ten when polypharmacy was defined more rigorously using five or more 
medications on the reference day. Furthermore, older prisoners faced polypharmacy (both 
definitions) more often than younger prisoners. The results remained significant for age group 
difference irrespective of how polypharmacy was defined. That older prisoners took 
significantly more medications than younger prisoners is an expected finding because of their 
higher disease burden (Fazel et al., 2001; Wangmo et al., 2015). 
Second, from our potentially adverse DDI analysis, we find that only one prisoner had 
a severe interaction potential (i.e. MediQ level 4, red). Also, on one reference day, more than 
a third of the prisoners who had taken two or more medications were concerned by a 
potentially adverse DDI with a moderate interaction potential (i.e. MediQ level 3, orange 
alert). However, there was no statistically significant difference between older and younger 
prisoners, that is, both were at equal risk. At first sight, this is an unexpected finding, since it 
is known that polypharmacy is a significant medical concern, particularly for the older 
population (Ballentine 2008; Hajjar et al., 2007) and presence of polypharmacy is associated 
with risk of DDIs (Johnell and Klarin 2007; Seymour and Routledge 1998; Vonbach et al., 
2008). Thus, one would expect older prisoners to have an elevated risk for potentially adverse 
DDI compared to younger prisoners simply because the risk increases with the number of 
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medications. When controlling for the number of medication taken, the risk of adverse DDI 
was higher in younger than older prisoners, though this result was short off being significant 
on the alpha=.05 level. The higher risk of younger prisoners for adverse DDI could be related 
to specific drug therapies that are required for a higher number of (former) drug users among 
younger prisoners.     
Third, medications that caused potentially adverse DDI in our study sample were 
drugs with pharmaceutical ingredients such as escitalopram, diazepam, quetiapine, diclofenac, 
methadone, and ibuprofen. Similarly, other studies have reported that common medications 
like aspirin and medications belonging to the following groups: anticoagulants and NSAIDs 
(Johnell and Klarin 2007; Percha and Altman 2013) often result in adverse DDIs. In light of 
very few studies illustrating the use of medications by prisoners (Elger et al., 2002; Elger et 
al., 2004; Williams et al., 2010), it is advisable for prison physicians to know of possible 
DDIs when prescribing these common drugs in prisons and other drugs (listed in Table 4) that 
caused DDI risk in our study.  
Finally, according to the individual rating of two pharmacists, considering individual 
cases (e.g. age, medical history) from the total sample, in 14 prisoners (3.7%) a clinically 
relevant adverse drug reaction was present (due to small numbers, it was not possible to 
statistically test for differences between age groups). Of the clinically relevant adverse drug 
reactions, nine were presumed prescription errors of clinical relevance, while the remaining 
was probably intentional. In certain situations, intentional DDIs are state of the art to 
prescribe a mixture of medications, which have tendencies to interact (Preston 2016; van 
Roon et al., 2005), and in these cases monitoring of the patient must be followed. In our 
study, we were unable to gather data on whether these patients with potential for adverse 
DDIs were under observation to ensure minimum harm or not. In their literature review, 
Griffiths and colleagues (2012) reported a lack of consistency between prescribers within a 
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facility and between different sites. They also noted that it can be problematic if prescribers 
work solely in correctional facilities since this may mean scarcity of unbiased information.  
 
Study limitations 
A key limitation of the study is that evaluation of polypharmacy and DDIs was not the 
main purpose of the overall project. This explains missing data as greater efforts were not put 
to ensure that all information could be obtained. This meant that we had to take certain 
decisions during data analysis to reach best data quality. Second, our results are based on data 
collected from the medical records of prisoners, thus, we cannot confidently state that the 
medications indicated as active on the reference day were effectively taken, but this is 
reasonable assumption. Related to the limitation above, we cannot control which other illegal 
substances (cannabis, heroin, cocaine – of which prevalence rates are high in prisons (see 
(Annaheim et al., 2018))) were taken in parallel to the prescribed drugs. We were not able to 
test for such interactions. Third, although it is stated that polypharmacy is more common in 
women than in men (e.g. (Fulton and Allen 2005)), our sample did not contain enough female 
prisoners (n=26) to allow a meaningful analysis on this sub-group. Fourth, MediQ identifies 
only two active substances at a time. The risks of multiple DDIs, hence, may be 
underestimated. Finally, the number of medications taken can be a conservative estimate since 
four prisons either did not provide or only provided limited access to information related to 
psychiatric care. Thus, there is risk of under-reporting of psychotropic medications included 
in our analysis.   
Conclusion 
To our knowledge, this is the first attempt at the national level to explore this topic. 
Although we were not able to improve the therapy for the individual patient as part of our 
study because of its retrospective nature, it provides data to better understand the specific care 
situations of older and younger prisoners and to improve medication safety when caring for 
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these groups. Older prisoners are at a higher risk for polypharmacy than younger prisoners but 
their risk for potentially adverse DDI is not significantly different from that of younger 
prisoners. Adequate medication practices in prisons require necessary considerations to 
specific sub-groups. This means paying special attention to older prisoners who are at risk for 
polypharmacy, on the one hand, and on younger prisoners who are at risk of very complex 
drug therapies (often involving opioid substitution treatments), on the other hand.  
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Table 1: Prevalence (%) of polypharmacy among younger (n=190) and older (n=190) prisoners when 
considering number of medications taken on one reference day 
 
Number of medications per 
individual 
Younger prisoners  
n (%) 
Older prisoners  
n (%) 
Total  
n (%) 
0 114 (60.0) 82 (43.2) 196 (51.6) 
1 39 (20.5) 31 (16.3) 70 (18.4) 
2 19 (10.0) 23 (12.1) 42 (11.1) 
3 10 (5.3) 14 (7.4) 24 (6.3) 
4 2 (1.1) 12 (6.3) 14 (3.7) 
5 or more 6 (3.2) 28 (14.7) 34 (8.9) 
Mean (SD)a  2.1 (1.7) 3.8 (3.3) 3.1 (2.9) 
Median, mode, maximum a  1, 1, 9 2.5, 1, 16 2, 1, 16 
aMean, median and mode are calculated based on all individuals with at least one medication on reference day: Young: n=76, Old: n=108. 
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Table 2: Differences between younger and older prisoners for number of medications taken, risk of 
polypharmacy, and potentially adverse drug-drug interactions (DDIs) 
 B SE t-
value 
Risk Ratio/ 
Odds ratioa 
95% CI for 
Risk/Odds ratio 
p-
value 
n 
Number of 
medications 
0.860 0.281 3.05 2.36 1.35, 4.11 .002 380 
Polypharmacy  
2+ medications 
1.104 0.348 3.17 3.01 1.52, 5.98 .002 380 
Polypharmacy  
5+ medications 
1.709 0.807 2.12 5.52 1.13, 27.02 .035 380 
Potentially adverse 
DDIb 
-0.063 0.414 -0.10 0.94 
 
0.42, 2.11 .879 114d 
Potentially adverse 
DDIc 
-1.076 0.594 -1.81 0.34 0.10, 1.10 .073 114d 
B = Coefficient indicating the difference between the two age groups; SE = Standard Error of B; a Risk ratio denotes by which factor the 
number of medications is higher in older compared to younger prisoners. Odds ratio denotes by which factor the odds for polypharmacy is 
higher in older prisoners than in younger prisoners; b Not controlled for number of medications.  We used a general linear model (GLM) 
rather than a GLMM due to fitting problems resulting from the fact that the estimated variance for the random intercept was redundant; c 
Controlling for number of medications; d Individuals with ≥ 2 medications on reference day. 
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Table 3: Potentially adverse drug-drug interactions among younger and older prisoners according to a 
clinical decision support software (MediQ) 
 Basis: Total combinations of active 
pharmaceutical ingredients 
Basis: Individuals with ≥2 
medications on reference day* 
Interaction potential 
(risk level) 
Younger 
(%) 
n=251 
Older (%) 
n=1383 
Total (%) 
n=1634 
Younger 
(%)  
n=37 
Older (%) 
n=77 
Total (%) 
n=114 
none (1, grey) 155  
(61.8) 
867  
(62.8) 
1022  
(62.6) 
21  
(56.8) 
64  
(83.1) 
85  
(74.6.3) 
low (2, yellow) 71  
(28.3) 
445  
(32.2) 
516  
(31.6) 
26  
(70.3) 
61  
(79.2) 
87  
(76.3) 
moderate (3, orange) 25  
(10.0) 
70  
(5.1) 
95  
(5.8) 
14  
(37.8) 
28  
(36.4) 
42  
(36.8) 
severe (4, red) 0  
(0.0) 
1  
(0.1) 
1  
(0.1) 
0  
(0.0) 
1  
(1.3) 
1  
(0.9) 
*The column numbers (n) do not add up to the total n (Younger, Older and Total) as some individuals have DDIs of different risk levels (e.g. 
an individual can have two level 3 and one level 2 alerts). 
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Table 4: Active pharmaceutical ingredients (in alphabetical order) most often involved in potentially 
adverse drug-drug interactions (DDI) of moderate risk (level 3, orange) in prisoners 
Active pharmaceutical 
ingredient 
(medication/product 
names) 
Individuals 
affected by 
DDI * N=380 
Total with this 
prescription  
N=380 
Risk ratio** 
(number of DDI / 
total with 
prescription) 
Potentially adversely 
interacting with (active 
pharmaceutical ingredients) 
Acetylsalicylic acid 
(Aspirin Cardio, Cardiax) 
10 (2.6 %) 23 (6.1 %) 0.43 
Budenosid, Clopidogrel, 
Diclofenac, Heparine, Ibuprofen, 
Naproxen, Phenprocoumon 
Diazepam (Valium Roche, 
Paceum, Psychopax) 
4 (1.1 %) 5 (1.3 %) 0.80 
Esomeprazol, Methadone, 
Tizanidin, Zuclopenthixol 
Diclofenac (Olfen, Cofec) 4 (1.1 %) 7 (1.8 %) 0.57 
Acetylsalicylic acid, Candesartan, 
Ibuprofen, Lisinopril 
Escitalopram (Cipralex, 
Citalopram Actavis) 
4 (1.1 %) 4 (1.1 %) 1.00 
Olanzapin, Omeprazol, Tizandin, 
Topiramat, Quetiapine 
Ibuprofen (Irfen, Spedifen, 
Brufen) 
7 (1.8 %) 13 (3.4 %) 0.54 
Acetylsalicylic acid, Budenosid, 
Diclofenac, Enalapril, Flecainid, 
Irbesartan, Lisinopril, Naproxen, 
Valsartan, Venlafaxin 
Lisinopril (Lisitril, 
Lisinopril, Prinil Mepha) 
6 (1.6 %) 13 (3.4 %) 0.46 
Diclofenac, Ibuprofen, Naproxen, 
Spironolacton 
Methadone (Methadon) 6 (1.6 %) 11 (2.9 %) 0.55 
Diazepam, Lorazepam, 
Midazolam, Propranolol, 
Quetiapine, Tizanidin, Tramadol, 
Zolpidem 
Omeprazole (Esomep, 
Omeprazol, Nexium) 
6 (1.6 %) 24 (6.3 %) 0.25 
Clopidogrel, Diazepam, 
Escitalopram, Pantoprazol, 
Phenprocoumon 
Quetiapine (Seroquel) 6 (1.6 %) 9 (2.4 %) 0.67 
Amitryptilin, Escitalopram, 
Methadone, Mirtazapin, 
Risperidon, Valproat 
*Listed are only those medications involved in potentially adverse DDI in more than three individuals. 
**Note that numbers for most common prescriptions are rather low and, thus, calculated risk ratios might be influenced by chance. 
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Table 5: Clinical relevance of adverse drug interactions among younger and older prisoners according to 
individual ratings of two pharmacists 
 Basis: Number of potentially adverse drug 
combinations (a) 
Basis: Individuals with at least one 
potentially adverse DDI (b) 
 Younger (%) 
n=25 
Older (%) 
n=70 
Total (%) 
n=95 
Younger (%) 
n=14 
Older (%) 
n=28 
Total (%) 
n=42 
A. Clinically relevant 8  
(32.0) 
11  
(15.7) 
19  
(20.0) 
5  
(35.7) 
9  
(32.1) 
14  
(33.3) 
   A1. presumed     
   prescription error 
4  
(16.0) 
8  
(11.4) 
12  
(12.6) 
3  
(21.4) 
6 
 (7.8) 
9  
(21.4) 
   A2. no better  
   solution available 
4  
(16.0) 
3 
(4.3) 
7 
(7.4) 
2  
(14.3) 
3 
 (3.9) 
5  
(11.9) 
B. Clinically not 
relevant 
1 
(4.0) 
20  
(28.6) 
21  
(22.1) 
0 
(0.0) 
5 
 (6.5) 
5 
(11.9) 
   B1. state of the   
   art prescription 
1 
(4.0) 
18  
(25.7) 
19  
(20.0) 
0 
(0.0) 
5 
 (6.5) 
5 
(11.9) 
   B2. harmless  
   prescription error 
0 
(0.0) 
2 
(2.9) 
2 
(2.1) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
C. Possibly clinically 
relevant 16 (64.0) 
39 
(55.7) 
55 
(57.9) 
9 
(64.3) 
14 
(18.2) 
23 
(54.8) 
(a) counted are all drug combinations, i.e. multiple per individual 
(b) counted is the most serious combination per individual (i.e. A1 > A2 > C > B2 >B1), only 
